


In the Claims

1(Original). A compound of formula (I):



(I)

wherein X and Y are each CR¹ or N;

one of R¹⁰ and R¹¹ is R¹ and the other is W;


each R¹ is hydrogen, halogen, hydroxy, cyano, amino, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl or haloC₁₋₄alkoxy;

W is a phenyl ring or a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, which ring is optionally substituted by halogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, cyano, nitro, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, carboxy, hydroxyC₁₋₆alkyl or aminoC₁₋₆alkyl; and

Z is a phenyl ring or a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, which ring is substituted at least at the position *para* to the attachment of the ring to the rest of the molecule by halogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, cyano, nitro, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, carboxy, hydroxyC₁₋₆alkyl or aminoC₁₋₆alkyl;

or a pharmaceutically acceptable salt thereof.

2(Original). A compound of claim 1 represented by formula (IA);



(IA)

wherein W is phenyl or pyridyl optionally substituted by halogen, C₁₋₂alkyl, C₁₋₂alkoxy, haloC₁₋₂alkyl or haloC₁₋₂alkoxy; and

Z is phenyl or pyridyl substituted at the position *para* to the point of attachment to the rest of the molecule by halogen, C₁₋₂alkyl, C₁₋₂alkoxy, haloC₁₋₂alkyl or haloC₁₋₂alkoxy;

or a pharmaceutically acceptable salt thereof.

3(Original). A compound selected from:

1,2-dihydro-2-(4-trifluoromethylphenyl)-6-(3-trifluoromethyl-2-pyridinyl)-3H-indazol-3-one;

1,2-dihydro-6-(3-methyl-2-pyridinyl)-2-(4-trifluoromethylphenyl)-3H-indazol-3-one;

1,2-dihydro-2-(4-trifluoromethylphenyl)-5-(3-trifluoromethyl-2-pyridinyl)-3H-indazol-3-one;

1,2-dihydro-6-(2-methoxyphenyl)-2-(4-trifluoromethylphenyl)-3H-indazol-3-one; and

1,2-dihydro-6-(3-methyl-2-pyridinyl)-2-(4-trifluoromethylphenyl)-3H-pyrazolo [3,4-b]pyridin-3-one;

or a pharmaceutically acceptable salt thereof.

4(Currently Amended). A pharmaceutical composition comprising ~~a one or more~~ compounds of ~~any one of~~ claims 1-3, or pharmaceutically acceptable salts thereof in association with a pharmaceutically acceptable carrier or excipient.

5(Currently Amended). ~~A compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body~~ A method for treating for or preventing of a disease or condition in

which pain and/or inflammation predominates comprising administering a compound of claim 1, or a composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.

6. Cancel.

7. Cancel.

8. Cancel.

9. Cancel.

10. Cancel.